EyePoint, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving EyePoint, Inc. now
Current reporting with the operating signal separated from the noise.
EyePoint, Inc.: EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME)
The story matters when it changes EyePoint, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
Investors are testing whether EyePoint, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest EYPT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
EyePoint, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →